The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study

[1]  M. Regueiro,et al.  Postoperative Infliximab Is Not Associated with An Increase in Adverse Events in Crohn’s Disease , 2011, Digestive Diseases and Sciences.

[2]  W. Sandborn,et al.  Perioperative Anti-Tumor Necrosis Factor Therapy Does Not Increase the Rate of Early Postoperative Complications in Crohn’s Disease , 2010, Journal of Gastrointestinal Surgery.

[3]  Y. Yamashita,et al.  Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? , 2010, Hepato-gastroenterology.

[4]  Takayuki Yamamoto,et al.  Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: A prospective pilot study , 2009, Inflammatory bowel diseases.

[5]  M. Regueiro,et al.  Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.

[6]  K. Sheahan,et al.  Long‐term clinical results of ileocecal resection for Crohn's disease , 2007, Inflammatory bowel diseases.

[7]  D. Binion,et al.  Clinical Factors Contributing to Rapid Reoperation for Crohn’s Disease Patients Undergoing Resection and/or Strictureplasty , 2007, Journal of Gastrointestinal Surgery.

[8]  C. Avellini,et al.  Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. , 2007, Archives of internal medicine.

[9]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  C. Avellini,et al.  Prevention of postoperative recurrence of Crohn's disease by infliximab. , 2006, European journal of gastroenterology & hepatology.

[11]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[12]  W. Sandborn,et al.  The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. , 2004, Gastroenterology.

[13]  W. Harmsen,et al.  Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy , 2004, American Journal of Gastroenterology.

[14]  P. Rutgeerts,et al.  The risk of post‐operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study , 2004, Alimentary pharmacology & therapeutics.

[15]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[16]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[17]  M. Regueiro,et al.  Treatment of Perianal Fistulizing Crohn's Disease with Infliximab Alone or as an Adjunct to Exam Under Anesthesia with Seton Placement , 2003, Inflammatory bowel diseases.

[18]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[19]  N. Scott,et al.  Mechanisms of intestinal failure in Crohn's disease , 2001, Diseases of the colon and rectum.

[20]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[21]  F. Casellas,et al.  Impact of surgery for Crohn's disease on health-related quality of life , 2000, American Journal of Gastroenterology.

[22]  B. Wolff,et al.  Total abdominal colectomy and ileorectal anastomosis for inflammatory bowel disease , 1997, Diseases of the colon and rectum.

[23]  D. Jewell,et al.  Preventing postoperative recurrence of Crohn's disease , 1997, The British journal of surgery.

[24]  M. Cottone,et al.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. , 1997, Gastroenterology.

[25]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[26]  Y. Yazdanpanah,et al.  Impact of surgery on quality of life in Crohn's disease. , 1997, The American journal of gastroenterology.

[27]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[28]  J. Hay,et al.  Inflammatory Bowel Disease: Costs‐of-Illness , 1992, Journal of clinical gastroenterology.

[29]  T. Balestracci,et al.  Primary and recurrent Crohn's disease. Experience with 1379 patients. , 1991, Annals of surgery.

[30]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[31]  D. Sachar,et al.  The problem of postoperative recurrence of Crohn's disease. , 1990, The Medical clinics of North America.

[32]  B. G. Olsen,et al.  Life prospects and quality of life in patients with Crohn's disease. , 1987, Gut.

[33]  M. R. Lock,et al.  Recurrence and reoperation for Crohn's disease: the role of disease location in prognosis. , 1981, The New England journal of medicine.

[34]  H. Mekhjian,et al.  National Cooperative Crohn's Disease Study: factors determining recurrence of Crohn's disease after surgery. , 1979, Gastroenterology.